SUBSCRIBE
SUBSCRIBE

Johnson & Johnson Family of Companies

NEWS
Pharm Country
The Robotic Have-Not: How Johnson & Johnson Plans To Woo Hospitals, Knee Surgeons
March 17, 2017
 · 
1 min read
Pharm Country
The 3 Most Important Numbers For Johnson & Johnson
March 13, 2017
 · 
1 min read
Job Trends
400 Johnson & Johnson Jobs at Risk in Scotland
March 10, 2017
 · 
1 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Business
Backed by Johnson & Johnson, Fusion Pharma Launches With $25 Million
February 23, 2017
 · 
2 min read
Deals
So Close, Yet So Far Away: How Sanofi Lost to Johnson & Johnson in the Epic $30 Billion Battle for Actelion
February 16, 2017
 · 
1 min read
Pharm Country
Who’s Johnson & Johnson’s Stepchild? Its Consumer Diabetes Device Biz
February 3, 2017
 · 
1 min read
Business
The Story Of A Johnson & Johnson Refugee Scientist
February 1, 2017
 · 
1 min read
Deals
How a Johnson & Johnson Corporate Jet Had Hedge Funds Betting Big on an Actelion Deal
January 27, 2017
 · 
1 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Pharm Country
This Drug Could be Johnson & Johnson’s Next Billion-Dollar Blockbuster
January 26, 2017
 · 
3 min read
Load More
AWARDS
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Press Releases
European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
December 22, 2025
 · 
14 min read
Press Releases
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
December 19, 2025
 · 
6 min read
Press Releases
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
December 18, 2025
 · 
33 min read
Press Releases
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results - December 15, 2025
December 16, 2025
 · 
1 min read
Press Releases
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors
December 16, 2025
 · 
4 min read
Press Releases
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
December 15, 2025
 · 
20 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
18 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
28 min read
Press Releases
Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 9, 2025
 · 
1 min read
Press Releases
Earlier use of CARVYKTI®▼ (ciltacabtagene autoleucel) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
December 8, 2025
 · 
15 min read
Load More